Nicolet Advisory Services LLC Raises Stock Position in Repligen Co. (NASDAQ:RGEN)

Nicolet Advisory Services LLC increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 6.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,254 shares of the biotechnology company’s stock after acquiring an additional 201 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Repligen were worth $452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Andra AP fonden purchased a new stake in shares of Repligen in the 2nd quarter valued at about $25,000. International Assets Investment Management LLC purchased a new stake in Repligen in the second quarter valued at approximately $33,000. UMB Bank n.a. boosted its holdings in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 130 shares during the period. Lazard Asset Management LLC grew its position in shares of Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday. Finally, JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Trading Up 0.6 %

Shares of RGEN stock opened at $142.58 on Friday. The business’s fifty day moving average price is $140.26 and its 200 day moving average price is $143.44. The firm has a market capitalization of $7.99 billion, a PE ratio of -385.34, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 5.56. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the firm earned $0.23 EPS. The business’s revenue was up 9.7% on a year-over-year basis. As a group, sell-side analysts forecast that Repligen Co. will post 1.52 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.